SCHEMBL2092341

SCHEMBL2092341

Cc1scnc1-c1cccc(F)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 4/20 0.46
ADORA1 P30542 3/20 0.46
KDM4E B2RXH2 2/20 0.42
MEN1 O00255 1/20 0.42
MAPT P10636 1/20 0.42
KMT2A Q03164 1/20 0.42
ADORA2B P29275 1/20 0.40
ACHE P22303 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
THPO P40225 1/20 0.39
DPP4 P27487 1/20 0.39
CHRNB4 P30926 1/20 0.39
CHRNA3 P32297 1/20 0.39
NISCH Q9Y2I1 1/20 0.39
LMNA P02545 1/20 0.39
PMP22 Q01453 1/20 0.39
ALDH1A2 O94788 1/20 0.38
PIM1 P11309 1/20 0.38
TDO2 P48775 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2092339 0.79 KDM4E (0.42) ADORA2AADORA1KDM4EMEN1MAPT
SCHEMBL2089600 0.77 KDM4E (0.40) ADORA1KDM4EMEN1MAPTKMT2A
SCHEMBL14754357 0.77 ABL1 (0.40) KDM4ECYP1A2CYP3A4
SCHEMBL7947668 0.76 CYP1A2 (0.48) ADORA2AADORA1KDM4EMEN1MAPT
SCHEMBL27574718 0.76 DPP4 (0.43) ADORA2AADORA1KDM4EMEN1MAPT
SCHEMBL24508717 0.74 ALDH1A2 (0.50) ADORA2AKDM4EMEN1MAPTKMT2A
SCHEMBL25511499 0.74 ADORA2A (0.42) ADORA2AADORA1KDM4EMEN1MAPT
SCHEMBL30166468 0.74 ADORA2A (0.42) ADORA2AADORA1KDM4EMEN1MAPT
SCHEMBL24508625 0.73 TRPM8 (0.59) KDM4EMEN1MAPTKMT2ACYP1A2
SCHEMBL2093695 0.72 ALDH1A1 (0.46) ADORA2AADORA1KDM4EMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed
EP-1678185-A1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-07-12 EP disclosed
WO-2005042542-A1 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 ADORA2A 1493/4885ADORA1 683/4885KDM4E 4578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.